152
Participants
Start Date
August 4, 2021
Primary Completion Date
November 9, 2022
Study Completion Date
February 3, 2023
Low Dose RBT-1
intravenous administration
High Dose RBT-1
intravenous administration
Placebo
intravenous administration
The Alfred Hospital, Melbourne
Gold Cost University Hospital & Health Services, Southport
Columbia University Irving Medical Center, New York
New York Presbyterian-Queens, Flushing
Rochester General Hospital Center for Clinical Research, Rochester
MedStar Health Research Institute, Inc., Washington D.C.
Heart Center Research, LLC, Huntsville
Lutheran Medical Group, Fort Wayne
Indiana University Health Southern Indiana, Bloomington
MyMichigan Medical Center, Midland
McLaren Greater Lansing, Lansing
Mayo Clinic Rochester, Rochester
University of Chicago Hospital Anesthesia and Critical Care, Chicago
University of Texas Southwestern Medical Center, Dallas
Keck Hospital of USC, Los Angeles
Santa Barbara Cottage Hospital, Santa Barbara
Stanford University Medical Center, Stanford
Yale University School of Medicine, New Haven
Brigham and Women's Hospital, Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Flinders Medical Centre, Bedford Park
Monash Medical Centre, Clayton
St-John Regional Hospital, Saint John
Hamilton Health Sciences Corporation, Hamilton
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec
Renibus Therapeutics, Inc.
INDUSTRY